nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—CYP2D6—Gefitinib—lung cancer	0.0307	0.108	CbGbCtD
Asenapine—CYP2D6—Vinorelbine—lung cancer	0.0236	0.0832	CbGbCtD
Asenapine—CYP1A2—Erlotinib—lung cancer	0.022	0.0775	CbGbCtD
Asenapine—CYP3A4—Topotecan—lung cancer	0.0213	0.0751	CbGbCtD
Asenapine—CYP3A4—Gefitinib—lung cancer	0.0195	0.0687	CbGbCtD
Asenapine—CYP3A4—Teniposide—lung cancer	0.0189	0.0666	CbGbCtD
Asenapine—CYP2D6—Erlotinib—lung cancer	0.0181	0.0639	CbGbCtD
Asenapine—CYP1A2—Etoposide—lung cancer	0.0159	0.0561	CbGbCtD
Asenapine—CYP3A4—Vinorelbine—lung cancer	0.015	0.0529	CbGbCtD
Asenapine—CYP2D6—Vinblastine—lung cancer	0.0146	0.0513	CbGbCtD
Asenapine—HTR2A—phrenic nerve—lung cancer	0.013	0.214	CbGeAlD
Asenapine—CYP3A4—Crizotinib—lung cancer	0.012	0.0421	CbGbCtD
Asenapine—CYP3A4—Erlotinib—lung cancer	0.0115	0.0406	CbGbCtD
Asenapine—CYP3A4—Paclitaxel—lung cancer	0.0106	0.0372	CbGbCtD
Asenapine—CYP3A4—Irinotecan—lung cancer	0.0104	0.0367	CbGbCtD
Asenapine—CYP3A4—Vinblastine—lung cancer	0.00926	0.0326	CbGbCtD
Asenapine—CYP2D6—Doxorubicin—lung cancer	0.00894	0.0315	CbGbCtD
Asenapine—CYP3A4—Etoposide—lung cancer	0.00834	0.0294	CbGbCtD
Asenapine—CYP3A4—Docetaxel—lung cancer	0.00763	0.0269	CbGbCtD
Asenapine—HTR7—pulmonary artery—lung cancer	0.00758	0.124	CbGeAlD
Asenapine—CYP3A4—Doxorubicin—lung cancer	0.00569	0.02	CbGbCtD
Asenapine—HTR2A—pulmonary artery—lung cancer	0.00473	0.0776	CbGeAlD
Asenapine—UGT1A4—respiratory system—lung cancer	0.004	0.0656	CbGeAlD
Asenapine—HRH2—cardiac atrium—lung cancer	0.00174	0.0286	CbGeAlD
Asenapine—SLC6A4—respiratory system—lung cancer	0.0015	0.0247	CbGeAlD
Asenapine—HRH2—lung—lung cancer	0.00133	0.0219	CbGeAlD
Asenapine—ADRB1—bronchus—lung cancer	0.00128	0.021	CbGeAlD
Asenapine—HTR7—respiratory system—lung cancer	0.00128	0.0209	CbGeAlD
Asenapine—DRD2—respiratory system—lung cancer	0.00121	0.0198	CbGeAlD
Asenapine—ADRB1—cardiac atrium—lung cancer	0.00108	0.0177	CbGeAlD
Asenapine—HTR7—epithelium—lung cancer	0.00107	0.0175	CbGeAlD
Asenapine—ADRA1A—epithelium—lung cancer	0.00103	0.0169	CbGeAlD
Asenapine—CYP1A2—respiratory system—lung cancer	0.00102	0.0167	CbGeAlD
Asenapine—ADRA2C—bronchus—lung cancer	0.000965	0.0158	CbGeAlD
Asenapine—HRH1—respiratory system—lung cancer	0.000953	0.0156	CbGeAlD
Asenapine—HTR7—trachea—lung cancer	0.000943	0.0155	CbGeAlD
Asenapine—HRH2—lymph node—lung cancer	0.000911	0.0149	CbGeAlD
Asenapine—ADRA2C—trachea—lung cancer	0.000867	0.0142	CbGeAlD
Asenapine—ADRB1—lung—lung cancer	0.000826	0.0136	CbGeAlD
Asenapine—ADRA2C—cardiac atrium—lung cancer	0.000814	0.0134	CbGeAlD
Asenapine—SLC6A4—lung—lung cancer	0.000798	0.0131	CbGeAlD
Asenapine—HRH1—epithelium—lung cancer	0.000796	0.0131	CbGeAlD
Asenapine—HTR2A—respiratory system—lung cancer	0.000796	0.013	CbGeAlD
Asenapine—HTR2B—lung—lung cancer	0.000791	0.013	CbGeAlD
Asenapine—ADRA2A—bronchus—lung cancer	0.00077	0.0126	CbGeAlD
Asenapine—HRH1—trachea—lung cancer	0.000704	0.0115	CbGeAlD
Asenapine—ADRA2A—trachea—lung cancer	0.000691	0.0113	CbGeAlD
Asenapine—HTR7—lung—lung cancer	0.000677	0.0111	CbGeAlD
Asenapine—HTR2A—epithelium—lung cancer	0.000665	0.0109	CbGeAlD
Asenapine—ADRA2A—cardiac atrium—lung cancer	0.00065	0.0107	CbGeAlD
Asenapine—DRD2—lung—lung cancer	0.000641	0.0105	CbGeAlD
Asenapine—ADRA2C—lung—lung cancer	0.000623	0.0102	CbGeAlD
Asenapine—HTR2A—trachea—lung cancer	0.000588	0.00964	CbGeAlD
Asenapine—HTR2B—lymph node—lung cancer	0.000541	0.00887	CbGeAlD
Asenapine—CYP1A2—lung—lung cancer	0.00054	0.00886	CbGeAlD
Asenapine—HRH1—lung—lung cancer	0.000506	0.0083	CbGeAlD
Asenapine—ADRA2A—lung—lung cancer	0.000497	0.00815	CbGeAlD
Asenapine—ADRA2C—lymph node—lung cancer	0.000426	0.00698	CbGeAlD
Asenapine—HTR2A—lung—lung cancer	0.000422	0.00693	CbGeAlD
Asenapine—HRH1—lymph node—lung cancer	0.000346	0.00567	CbGeAlD
Asenapine—ADRA2A—lymph node—lung cancer	0.00034	0.00557	CbGeAlD
Asenapine—Angioedema—Paclitaxel—lung cancer	0.000335	0.000908	CcSEcCtD
Asenapine—Leukopenia—Etoposide—lung cancer	0.000334	0.000907	CcSEcCtD
Asenapine—Hypotension—Gemcitabine—lung cancer	0.000333	0.000905	CcSEcCtD
Asenapine—Eye disorder—Docetaxel—lung cancer	0.000333	0.000904	CcSEcCtD
Asenapine—Anaphylactic shock—Cisplatin—lung cancer	0.000333	0.000903	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000332	0.000902	CcSEcCtD
Asenapine—Insomnia—Irinotecan—lung cancer	0.000331	0.000899	CcSEcCtD
Asenapine—Cardiac disorder—Docetaxel—lung cancer	0.000331	0.000898	CcSEcCtD
Asenapine—Vomiting—Topotecan—lung cancer	0.00033	0.000896	CcSEcCtD
Asenapine—Malaise—Paclitaxel—lung cancer	0.00033	0.000896	CcSEcCtD
Asenapine—Syncope—Paclitaxel—lung cancer	0.000328	0.000891	CcSEcCtD
Asenapine—Loss of consciousness—Etoposide—lung cancer	0.000328	0.000891	CcSEcCtD
Asenapine—Leukopenia—Paclitaxel—lung cancer	0.000328	0.00089	CcSEcCtD
Asenapine—Rash—Topotecan—lung cancer	0.000327	0.000889	CcSEcCtD
Asenapine—Hypersensitivity—Vinorelbine—lung cancer	0.000327	0.000888	CcSEcCtD
Asenapine—Dermatitis—Topotecan—lung cancer	0.000327	0.000888	CcSEcCtD
Asenapine—Vomiting—Erlotinib—lung cancer	0.000327	0.000887	CcSEcCtD
Asenapine—Dyspnoea—Irinotecan—lung cancer	0.000327	0.000887	CcSEcCtD
Asenapine—Nervous system disorder—Cisplatin—lung cancer	0.000326	0.000886	CcSEcCtD
Asenapine—Somnolence—Irinotecan—lung cancer	0.000326	0.000884	CcSEcCtD
Asenapine—Thrombocytopenia—Cisplatin—lung cancer	0.000326	0.000884	CcSEcCtD
Asenapine—Headache—Topotecan—lung cancer	0.000325	0.000883	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Gemcitabine—lung cancer	0.000325	0.000883	CcSEcCtD
Asenapine—Tachycardia—Cisplatin—lung cancer	0.000325	0.000881	CcSEcCtD
Asenapine—Rash—Erlotinib—lung cancer	0.000324	0.000879	CcSEcCtD
Asenapine—Dermatitis—Erlotinib—lung cancer	0.000324	0.000879	CcSEcCtD
Asenapine—Convulsion—Etoposide—lung cancer	0.000324	0.000878	CcSEcCtD
Asenapine—Angiopathy—Docetaxel—lung cancer	0.000323	0.000878	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—lung cancer	0.000323	0.000876	CcSEcCtD
Asenapine—Insomnia—Gemcitabine—lung cancer	0.000323	0.000876	CcSEcCtD
Asenapine—Dyspepsia—Irinotecan—lung cancer	0.000323	0.000875	CcSEcCtD
Asenapine—Hypertension—Etoposide—lung cancer	0.000322	0.000875	CcSEcCtD
Asenapine—Immune system disorder—Docetaxel—lung cancer	0.000322	0.000874	CcSEcCtD
Asenapine—Headache—Erlotinib—lung cancer	0.000322	0.000874	CcSEcCtD
Asenapine—Loss of consciousness—Paclitaxel—lung cancer	0.000322	0.000873	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—lung cancer	0.000322	0.000873	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—lung cancer	0.000322	0.000873	CcSEcCtD
Asenapine—Mediastinal disorder—Docetaxel—lung cancer	0.000321	0.000872	CcSEcCtD
Asenapine—Asthenia—Vinorelbine—lung cancer	0.000319	0.000865	CcSEcCtD
Asenapine—Dyspnoea—Gemcitabine—lung cancer	0.000318	0.000864	CcSEcCtD
Asenapine—Nausea—Vinblastine—lung cancer	0.000318	0.000862	CcSEcCtD
Asenapine—Somnolence—Gemcitabine—lung cancer	0.000317	0.000861	CcSEcCtD
Asenapine—Convulsion—Paclitaxel—lung cancer	0.000317	0.000861	CcSEcCtD
Asenapine—Gastrointestinal disorder—Irinotecan—lung cancer	0.000316	0.000859	CcSEcCtD
Asenapine—Hypertension—Paclitaxel—lung cancer	0.000316	0.000858	CcSEcCtD
Asenapine—Fatigue—Irinotecan—lung cancer	0.000316	0.000857	CcSEcCtD
Asenapine—Constipation—Irinotecan—lung cancer	0.000313	0.00085	CcSEcCtD
Asenapine—Mental disorder—Docetaxel—lung cancer	0.000312	0.000848	CcSEcCtD
Asenapine—Arthralgia—Paclitaxel—lung cancer	0.000312	0.000846	CcSEcCtD
Asenapine—Hypotension—Cisplatin—lung cancer	0.000311	0.000844	CcSEcCtD
Asenapine—Anxiety—Paclitaxel—lung cancer	0.000311	0.000843	CcSEcCtD
Asenapine—Malnutrition—Docetaxel—lung cancer	0.00031	0.000842	CcSEcCtD
Asenapine—Nausea—Topotecan—lung cancer	0.000308	0.000837	CcSEcCtD
Asenapine—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000308	0.000836	CcSEcCtD
Asenapine—Abdominal discomfort—Methotrexate—lung cancer	0.000308	0.000835	CcSEcCtD
Asenapine—Fatigue—Gemcitabine—lung cancer	0.000308	0.000835	CcSEcCtD
Asenapine—Constipation—Gemcitabine—lung cancer	0.000305	0.000828	CcSEcCtD
Asenapine—Nausea—Erlotinib—lung cancer	0.000305	0.000828	CcSEcCtD
Asenapine—Dry mouth—Paclitaxel—lung cancer	0.000305	0.000827	CcSEcCtD
Asenapine—Anaphylactic shock—Etoposide—lung cancer	0.000305	0.000827	CcSEcCtD
Asenapine—Dysgeusia—Docetaxel—lung cancer	0.000304	0.000825	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000303	0.000823	CcSEcCtD
Asenapine—Neutropenia—Methotrexate—lung cancer	0.0003	0.000815	CcSEcCtD
Asenapine—Anaphylactic shock—Paclitaxel—lung cancer	0.000299	0.000811	CcSEcCtD
Asenapine—Thrombocytopenia—Etoposide—lung cancer	0.000298	0.00081	CcSEcCtD
Asenapine—Muscle spasms—Docetaxel—lung cancer	0.000298	0.00081	CcSEcCtD
Asenapine—Tachycardia—Etoposide—lung cancer	0.000297	0.000807	CcSEcCtD
Asenapine—Dyspnoea—Cisplatin—lung cancer	0.000297	0.000805	CcSEcCtD
Asenapine—Shock—Paclitaxel—lung cancer	0.000294	0.000798	CcSEcCtD
Asenapine—Dizziness—Vinorelbine—lung cancer	0.000294	0.000797	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—lung cancer	0.000294	0.000797	CcSEcCtD
Asenapine—Nervous system disorder—Paclitaxel—lung cancer	0.000293	0.000795	CcSEcCtD
Asenapine—Thrombocytopenia—Paclitaxel—lung cancer	0.000293	0.000794	CcSEcCtD
Asenapine—Tachycardia—Paclitaxel—lung cancer	0.000292	0.000792	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—lung cancer	0.000291	0.000789	CcSEcCtD
Asenapine—Gastrointestinal disorder—Cisplatin—lung cancer	0.000287	0.00078	CcSEcCtD
Asenapine—Anaemia—Docetaxel—lung cancer	0.000287	0.000779	CcSEcCtD
Asenapine—Depression—Methotrexate—lung cancer	0.000285	0.000775	CcSEcCtD
Asenapine—Hypotension—Etoposide—lung cancer	0.000285	0.000773	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000284	0.00077	CcSEcCtD
Asenapine—Vomiting—Vinorelbine—lung cancer	0.000282	0.000767	CcSEcCtD
Asenapine—Rash—Vinorelbine—lung cancer	0.00028	0.00076	CcSEcCtD
Asenapine—Dermatitis—Vinorelbine—lung cancer	0.00028	0.00076	CcSEcCtD
Asenapine—Hypotension—Paclitaxel—lung cancer	0.000279	0.000758	CcSEcCtD
Asenapine—Stomatitis—Methotrexate—lung cancer	0.000279	0.000757	CcSEcCtD
Asenapine—Headache—Vinorelbine—lung cancer	0.000278	0.000755	CcSEcCtD
Asenapine—Syncope—Docetaxel—lung cancer	0.000278	0.000755	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—lung cancer	0.000278	0.000754	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—lung cancer	0.000278	0.000754	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—lung cancer	0.000273	0.00074	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000272	0.000739	CcSEcCtD
Asenapine—Dyspnoea—Etoposide—lung cancer	0.000272	0.000738	CcSEcCtD
Asenapine—Somnolence—Etoposide—lung cancer	0.000271	0.000735	CcSEcCtD
Asenapine—Hepatobiliary disease—Methotrexate—lung cancer	0.000271	0.000735	CcSEcCtD
Asenapine—Insomnia—Paclitaxel—lung cancer	0.00027	0.000734	CcSEcCtD
Asenapine—Hypersensitivity—Irinotecan—lung cancer	0.00027	0.000733	CcSEcCtD
Asenapine—Convulsion—Docetaxel—lung cancer	0.000269	0.00073	CcSEcCtD
Asenapine—Hypertension—Docetaxel—lung cancer	0.000268	0.000727	CcSEcCtD
Asenapine—Agranulocytosis—Methotrexate—lung cancer	0.000267	0.000725	CcSEcCtD
Asenapine—Dyspnoea—Paclitaxel—lung cancer	0.000266	0.000723	CcSEcCtD
Asenapine—Somnolence—Paclitaxel—lung cancer	0.000266	0.000721	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—lung cancer	0.000264	0.000717	CcSEcCtD
Asenapine—Nausea—Vinorelbine—lung cancer	0.000264	0.000716	CcSEcCtD
Asenapine—Gastrointestinal disorder—Etoposide—lung cancer	0.000263	0.000714	CcSEcCtD
Asenapine—Dyspepsia—Paclitaxel—lung cancer	0.000263	0.000714	CcSEcCtD
Asenapine—Asthenia—Irinotecan—lung cancer	0.000263	0.000714	CcSEcCtD
Asenapine—Fatigue—Etoposide—lung cancer	0.000263	0.000713	CcSEcCtD
Asenapine—Constipation—Etoposide—lung cancer	0.000261	0.000707	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—lung cancer	0.00026	0.000706	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—lung cancer	0.000258	0.000701	CcSEcCtD
Asenapine—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000258	0.0007	CcSEcCtD
Asenapine—Fatigue—Paclitaxel—lung cancer	0.000258	0.000699	CcSEcCtD
Asenapine—Asthenia—Gemcitabine—lung cancer	0.000256	0.000695	CcSEcCtD
Asenapine—Constipation—Paclitaxel—lung cancer	0.000256	0.000694	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—lung cancer	0.000253	0.000687	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—lung cancer	0.000253	0.000687	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—lung cancer	0.000251	0.000681	CcSEcCtD
Asenapine—Shock—Docetaxel—lung cancer	0.000249	0.000676	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—lung cancer	0.000248	0.000674	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—lung cancer	0.000248	0.000673	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—lung cancer	0.000247	0.000671	CcSEcCtD
Asenapine—Hypersensitivity—Cisplatin—lung cancer	0.000245	0.000665	CcSEcCtD
Asenapine—Dizziness—Irinotecan—lung cancer	0.000242	0.000658	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—lung cancer	0.000242	0.000656	CcSEcCtD
Asenapine—Eye disorder—Methotrexate—lung cancer	0.00024	0.000652	CcSEcCtD
Asenapine—Asthenia—Cisplatin—lung cancer	0.000239	0.000648	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—lung cancer	0.000238	0.000647	CcSEcCtD
Asenapine—Hypotension—Docetaxel—lung cancer	0.000237	0.000642	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—lung cancer	0.000234	0.000636	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—lung cancer	0.000233	0.000633	CcSEcCtD
Asenapine—Vomiting—Irinotecan—lung cancer	0.000233	0.000632	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—lung cancer	0.000232	0.00063	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—lung cancer	0.000232	0.000629	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—lung cancer	0.000231	0.000628	CcSEcCtD
Asenapine—Rash—Irinotecan—lung cancer	0.000231	0.000627	CcSEcCtD
Asenapine—Dermatitis—Irinotecan—lung cancer	0.000231	0.000626	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000231	0.000626	CcSEcCtD
Asenapine—Headache—Irinotecan—lung cancer	0.00023	0.000623	CcSEcCtD
Asenapine—Insomnia—Docetaxel—lung cancer	0.000229	0.000622	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—lung cancer	0.000227	0.000616	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—lung cancer	0.000226	0.000613	CcSEcCtD
Asenapine—Somnolence—Docetaxel—lung cancer	0.000225	0.000611	CcSEcCtD
Asenapine—Mental disorder—Methotrexate—lung cancer	0.000225	0.000611	CcSEcCtD
Asenapine—Rash—Gemcitabine—lung cancer	0.000225	0.000611	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—lung cancer	0.000225	0.00061	CcSEcCtD
Asenapine—Hypersensitivity—Etoposide—lung cancer	0.000225	0.000609	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—lung cancer	0.000224	0.000607	CcSEcCtD
Asenapine—Headache—Gemcitabine—lung cancer	0.000224	0.000607	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—lung cancer	0.000223	0.000605	CcSEcCtD
Asenapine—Hypersensitivity—Paclitaxel—lung cancer	0.00022	0.000598	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—lung cancer	0.000219	0.000595	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—lung cancer	0.000219	0.000595	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—lung cancer	0.000219	0.000594	CcSEcCtD
Asenapine—Asthenia—Etoposide—lung cancer	0.000219	0.000594	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—lung cancer	0.000219	0.000593	CcSEcCtD
Asenapine—Fatigue—Docetaxel—lung cancer	0.000218	0.000593	CcSEcCtD
Asenapine—Nausea—Irinotecan—lung cancer	0.000218	0.000591	CcSEcCtD
Asenapine—Constipation—Docetaxel—lung cancer	0.000217	0.000588	CcSEcCtD
Asenapine—Asthenia—Paclitaxel—lung cancer	0.000214	0.000582	CcSEcCtD
Asenapine—Nausea—Gemcitabine—lung cancer	0.000212	0.000575	CcSEcCtD
Asenapine—Vomiting—Cisplatin—lung cancer	0.000211	0.000574	CcSEcCtD
Asenapine—Rash—Cisplatin—lung cancer	0.00021	0.000569	CcSEcCtD
Asenapine—Dermatitis—Cisplatin—lung cancer	0.00021	0.000569	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—lung cancer	0.000208	0.000564	CcSEcCtD
Asenapine—Anaemia—Methotrexate—lung cancer	0.000207	0.000561	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—lung cancer	0.000206	0.00056	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—lung cancer	0.000202	0.000548	CcSEcCtD
Asenapine—Malaise—Methotrexate—lung cancer	0.000202	0.000548	CcSEcCtD
Asenapine—Dizziness—Etoposide—lung cancer	0.000202	0.000547	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—lung cancer	0.000201	0.000545	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—lung cancer	0.000201	0.000544	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—lung cancer	0.0002	0.000543	CcSEcCtD
Asenapine—Dizziness—Paclitaxel—lung cancer	0.000198	0.000536	CcSEcCtD
Asenapine—Nausea—Cisplatin—lung cancer	0.000198	0.000536	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—lung cancer	0.000195	0.000529	CcSEcCtD
Asenapine—Convulsion—Methotrexate—lung cancer	0.000194	0.000526	CcSEcCtD
Asenapine—Vomiting—Etoposide—lung cancer	0.000194	0.000526	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—lung cancer	0.000194	0.000526	CcSEcCtD
Asenapine—Rash—Etoposide—lung cancer	0.000192	0.000522	CcSEcCtD
Asenapine—Dermatitis—Etoposide—lung cancer	0.000192	0.000521	CcSEcCtD
Asenapine—Headache—Etoposide—lung cancer	0.000191	0.000518	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—lung cancer	0.00019	0.000517	CcSEcCtD
Asenapine—Vomiting—Paclitaxel—lung cancer	0.00019	0.000516	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—lung cancer	0.00019	0.000515	CcSEcCtD
Asenapine—Rash—Paclitaxel—lung cancer	0.000188	0.000511	CcSEcCtD
Asenapine—Dermatitis—Paclitaxel—lung cancer	0.000188	0.000511	CcSEcCtD
Asenapine—Headache—Paclitaxel—lung cancer	0.000187	0.000508	CcSEcCtD
Asenapine—Hypersensitivity—Docetaxel—lung cancer	0.000187	0.000507	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—lung cancer	0.000186	0.000505	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—lung cancer	0.000183	0.000495	CcSEcCtD
Asenapine—Asthenia—Docetaxel—lung cancer	0.000182	0.000493	CcSEcCtD
Asenapine—Nausea—Etoposide—lung cancer	0.000181	0.000491	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—lung cancer	0.000179	0.000486	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—lung cancer	0.000179	0.000486	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—lung cancer	0.000179	0.000485	CcSEcCtD
Asenapine—Agitation—Doxorubicin—lung cancer	0.000178	0.000483	CcSEcCtD
Asenapine—Nausea—Paclitaxel—lung cancer	0.000177	0.000482	CcSEcCtD
Asenapine—Malaise—Doxorubicin—lung cancer	0.000175	0.000474	CcSEcCtD
Asenapine—Syncope—Doxorubicin—lung cancer	0.000174	0.000471	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—lung cancer	0.000173	0.000471	CcSEcCtD
Asenapine—Hypotension—Methotrexate—lung cancer	0.000171	0.000463	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—lung cancer	0.00017	0.000462	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—lung cancer	0.000168	0.000455	CcSEcCtD
Asenapine—Dizziness—Docetaxel—lung cancer	0.000167	0.000455	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—lung cancer	0.000167	0.000454	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000166	0.000451	CcSEcCtD
Asenapine—Insomnia—Methotrexate—lung cancer	0.000165	0.000448	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—lung cancer	0.000165	0.000448	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—lung cancer	0.000164	0.000446	CcSEcCtD
Asenapine—Dyspnoea—Methotrexate—lung cancer	0.000163	0.000442	CcSEcCtD
Asenapine—Somnolence—Methotrexate—lung cancer	0.000162	0.00044	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—lung cancer	0.000161	0.000438	CcSEcCtD
Asenapine—Vomiting—Docetaxel—lung cancer	0.000161	0.000437	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—lung cancer	0.000161	0.000436	CcSEcCtD
Asenapine—Rash—Docetaxel—lung cancer	0.00016	0.000433	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—lung cancer	0.00016	0.000433	CcSEcCtD
Asenapine—Headache—Docetaxel—lung cancer	0.000159	0.000431	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—lung cancer	0.000158	0.000429	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—lung cancer	0.000158	0.000428	CcSEcCtD
Asenapine—Fatigue—Methotrexate—lung cancer	0.000157	0.000427	CcSEcCtD
Asenapine—Shock—Doxorubicin—lung cancer	0.000156	0.000422	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—lung cancer	0.000155	0.000421	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—lung cancer	0.000155	0.00042	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—lung cancer	0.000154	0.000419	CcSEcCtD
Asenapine—Nausea—Docetaxel—lung cancer	0.00015	0.000408	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—lung cancer	0.000148	0.000401	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000144	0.000391	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—lung cancer	0.000143	0.000388	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—lung cancer	0.000141	0.000383	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—lung cancer	0.000141	0.000381	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—lung cancer	0.000139	0.000378	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000136	0.00037	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—lung cancer	0.000136	0.00037	CcSEcCtD
Asenapine—Constipation—Doxorubicin—lung cancer	0.000135	0.000367	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—lung cancer	0.000134	0.000365	CcSEcCtD
Asenapine—Asthenia—Methotrexate—lung cancer	0.000131	0.000356	CcSEcCtD
Asenapine—Dizziness—Methotrexate—lung cancer	0.000121	0.000328	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—lung cancer	0.000116	0.000316	CcSEcCtD
Asenapine—Vomiting—Methotrexate—lung cancer	0.000116	0.000315	CcSEcCtD
Asenapine—Rash—Methotrexate—lung cancer	0.000115	0.000312	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—lung cancer	0.000115	0.000312	CcSEcCtD
Asenapine—Headache—Methotrexate—lung cancer	0.000114	0.00031	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—lung cancer	0.000113	0.000308	CcSEcCtD
Asenapine—Nausea—Methotrexate—lung cancer	0.000108	0.000294	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—lung cancer	0.000105	0.000284	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—lung cancer	0.0001	0.000273	CcSEcCtD
Asenapine—Rash—Doxorubicin—lung cancer	9.97e-05	0.000271	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—lung cancer	9.96e-05	0.00027	CcSEcCtD
Asenapine—Headache—Doxorubicin—lung cancer	9.9e-05	0.000269	CcSEcCtD
Asenapine—Nausea—Doxorubicin—lung cancer	9.39e-05	0.000255	CcSEcCtD
Asenapine—ADRA1A—Signaling Pathways—IL2—lung cancer	5.44e-06	1.9e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—lung cancer	5.44e-06	1.9e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—SRC—lung cancer	5.43e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—EP300—lung cancer	5.42e-06	1.89e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—lung cancer	5.42e-06	1.89e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—lung cancer	5.42e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—IL6—lung cancer	5.41e-06	1.89e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STAT3—lung cancer	5.41e-06	1.89e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK3—lung cancer	5.41e-06	1.89e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—JUN—lung cancer	5.41e-06	1.88e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—lung cancer	5.41e-06	1.88e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—lung cancer	5.4e-06	1.88e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—lung cancer	5.4e-06	1.88e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—JUN—lung cancer	5.39e-06	1.88e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—lung cancer	5.38e-06	1.88e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—lung cancer	5.37e-06	1.87e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTP1—lung cancer	5.36e-06	1.87e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—lung cancer	5.36e-06	1.87e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—lung cancer	5.34e-06	1.86e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—lung cancer	5.34e-06	1.86e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—lung cancer	5.34e-06	1.86e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—lung cancer	5.33e-06	1.86e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—lung cancer	5.33e-06	1.86e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—POMC—lung cancer	5.33e-06	1.86e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—lung cancer	5.33e-06	1.86e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—lung cancer	5.31e-06	1.85e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—lung cancer	5.3e-06	1.85e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—lung cancer	5.3e-06	1.85e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—JUN—lung cancer	5.29e-06	1.85e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—lung cancer	5.29e-06	1.84e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—lung cancer	5.29e-06	1.84e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—lung cancer	5.29e-06	1.84e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—lung cancer	5.26e-06	1.84e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—lung cancer	5.26e-06	1.83e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—lung cancer	5.26e-06	1.83e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—lung cancer	5.26e-06	1.83e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—lung cancer	5.25e-06	1.83e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—lung cancer	5.24e-06	1.83e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—lung cancer	5.24e-06	1.83e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—lung cancer	5.23e-06	1.82e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—lung cancer	5.23e-06	1.82e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—lung cancer	5.22e-06	1.82e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CAT—lung cancer	5.22e-06	1.82e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—lung cancer	5.22e-06	1.82e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—lung cancer	5.21e-06	1.82e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—APOA1—lung cancer	5.19e-06	1.81e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—CREBBP—lung cancer	5.19e-06	1.81e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—lung cancer	5.19e-06	1.81e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—lung cancer	5.18e-06	1.81e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—lung cancer	5.17e-06	1.8e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—lung cancer	5.15e-06	1.8e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—lung cancer	5.14e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—lung cancer	5.14e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—lung cancer	5.14e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	5.13e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—lung cancer	5.12e-06	1.79e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	5.11e-06	1.78e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—lung cancer	5.11e-06	1.78e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—lung cancer	5.1e-06	1.78e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—lung cancer	5.1e-06	1.78e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—lung cancer	5.1e-06	1.78e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—lung cancer	5.1e-06	1.78e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—lung cancer	5.09e-06	1.78e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—lung cancer	5.09e-06	1.77e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—lung cancer	5.08e-06	1.77e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—lung cancer	5.07e-06	1.77e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EP300—lung cancer	5.07e-06	1.77e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—lung cancer	5.06e-06	1.77e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—lung cancer	5.06e-06	1.76e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—lung cancer	5.03e-06	1.75e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—lung cancer	5.03e-06	1.75e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—lung cancer	5.03e-06	1.75e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—lung cancer	5e-06	1.74e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—lung cancer	5e-06	1.74e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—lung cancer	4.99e-06	1.74e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—TYMS—lung cancer	4.99e-06	1.74e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EP300—lung cancer	4.99e-06	1.74e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EP300—lung cancer	4.98e-06	1.74e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.97e-06	1.73e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—lung cancer	4.96e-06	1.73e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—lung cancer	4.96e-06	1.73e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—lung cancer	4.94e-06	1.72e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTM1—lung cancer	4.93e-06	1.72e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—lung cancer	4.93e-06	1.72e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—SRC—lung cancer	4.93e-06	1.72e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—lung cancer	4.92e-06	1.72e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—lung cancer	4.92e-06	1.72e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—JUN—lung cancer	4.92e-06	1.71e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—lung cancer	4.9e-06	1.71e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—lung cancer	4.89e-06	1.71e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—lung cancer	4.88e-06	1.7e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EP300—lung cancer	4.88e-06	1.7e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—lung cancer	4.87e-06	1.7e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—lung cancer	4.87e-06	1.7e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—lung cancer	4.86e-06	1.69e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ALB—lung cancer	4.86e-06	1.69e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—SRC—lung cancer	4.85e-06	1.69e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—SRC—lung cancer	4.84e-06	1.69e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—lung cancer	4.81e-06	1.68e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—lung cancer	4.8e-06	1.67e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—lung cancer	4.8e-06	1.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—lung cancer	4.78e-06	1.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	4.77e-06	1.66e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—lung cancer	4.76e-06	1.66e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—lung cancer	4.76e-06	1.66e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—lung cancer	4.75e-06	1.66e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—lung cancer	4.75e-06	1.66e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—SRC—lung cancer	4.75e-06	1.66e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—lung cancer	4.74e-06	1.65e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—lung cancer	4.74e-06	1.65e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—lung cancer	4.74e-06	1.65e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—lung cancer	4.72e-06	1.65e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—lung cancer	4.71e-06	1.64e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—lung cancer	4.71e-06	1.64e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—lung cancer	4.71e-06	1.64e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—lung cancer	4.68e-06	1.63e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—lung cancer	4.68e-06	1.63e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CYP1A1—lung cancer	4.67e-06	1.63e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—lung cancer	4.67e-06	1.63e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—lung cancer	4.66e-06	1.63e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—lung cancer	4.66e-06	1.63e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—lung cancer	4.65e-06	1.62e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—lung cancer	4.65e-06	1.62e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—lung cancer	4.64e-06	1.62e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ERCC2—lung cancer	4.63e-06	1.62e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—lung cancer	4.62e-06	1.61e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—lung cancer	4.62e-06	1.61e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—lung cancer	4.59e-06	1.6e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—lung cancer	4.58e-06	1.6e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—lung cancer	4.58e-06	1.6e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—lung cancer	4.57e-06	1.59e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—lung cancer	4.54e-06	1.58e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EP300—lung cancer	4.54e-06	1.58e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—lung cancer	4.53e-06	1.58e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—POMC—lung cancer	4.51e-06	1.57e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—lung cancer	4.51e-06	1.57e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—lung cancer	4.5e-06	1.57e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—lung cancer	4.47e-06	1.56e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—lung cancer	4.46e-06	1.56e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—lung cancer	4.46e-06	1.55e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	4.42e-06	1.54e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—lung cancer	4.42e-06	1.54e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—SRC—lung cancer	4.41e-06	1.54e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CREBBP—lung cancer	4.4e-06	1.53e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—lung cancer	4.4e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—lung cancer	4.37e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—lung cancer	4.37e-06	1.52e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—lung cancer	4.34e-06	1.52e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—lung cancer	4.34e-06	1.51e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—lung cancer	4.34e-06	1.51e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—lung cancer	4.32e-06	1.51e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—lung cancer	4.32e-06	1.51e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—lung cancer	4.3e-06	1.5e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—lung cancer	4.3e-06	1.5e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—lung cancer	4.29e-06	1.5e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—lung cancer	4.28e-06	1.49e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—lung cancer	4.27e-06	1.49e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—lung cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—lung cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—lung cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—lung cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—lung cancer	4.25e-06	1.48e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—lung cancer	4.24e-06	1.48e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—lung cancer	4.24e-06	1.48e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—lung cancer	4.22e-06	1.47e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—lung cancer	4.17e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—lung cancer	4.16e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	4.13e-06	1.44e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—lung cancer	4.13e-06	1.44e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—lung cancer	4.13e-06	1.44e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ALB—lung cancer	4.12e-06	1.44e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—lung cancer	4.11e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—lung cancer	4.09e-06	1.43e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—lung cancer	4.08e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—lung cancer	4.06e-06	1.42e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—lung cancer	4.06e-06	1.41e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—lung cancer	4.04e-06	1.41e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—lung cancer	4.04e-06	1.41e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—lung cancer	4.01e-06	1.4e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—lung cancer	4.01e-06	1.4e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—APOA1—lung cancer	4.01e-06	1.4e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—lung cancer	4.01e-06	1.4e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—lung cancer	4e-06	1.4e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—lung cancer	4e-06	1.39e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—lung cancer	3.95e-06	1.38e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—lung cancer	3.95e-06	1.38e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—lung cancer	3.95e-06	1.38e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—lung cancer	3.93e-06	1.37e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—lung cancer	3.93e-06	1.37e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—lung cancer	3.92e-06	1.37e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—lung cancer	3.87e-06	1.35e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—lung cancer	3.87e-06	1.35e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—lung cancer	3.82e-06	1.33e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—lung cancer	3.78e-06	1.32e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—lung cancer	3.76e-06	1.31e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—lung cancer	3.75e-06	1.31e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—lung cancer	3.71e-06	1.29e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—lung cancer	3.69e-06	1.29e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—lung cancer	3.68e-06	1.28e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—lung cancer	3.66e-06	1.28e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—lung cancer	3.66e-06	1.28e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—lung cancer	3.65e-06	1.27e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—lung cancer	3.65e-06	1.27e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—lung cancer	3.63e-06	1.27e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—lung cancer	3.63e-06	1.26e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—lung cancer	3.61e-06	1.26e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	3.61e-06	1.26e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—lung cancer	3.6e-06	1.26e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—lung cancer	3.57e-06	1.24e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—lung cancer	3.57e-06	1.24e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—lung cancer	3.56e-06	1.24e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—EP300—lung cancer	3.54e-06	1.23e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—lung cancer	3.49e-06	1.22e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—lung cancer	3.49e-06	1.22e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—POMC—lung cancer	3.48e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—lung cancer	3.47e-06	1.21e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—lung cancer	3.47e-06	1.21e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—lung cancer	3.41e-06	1.19e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—lung cancer	3.41e-06	1.19e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CREBBP—lung cancer	3.39e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—lung cancer	3.37e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	3.36e-06	1.17e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—lung cancer	3.34e-06	1.17e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—lung cancer	3.32e-06	1.16e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—lung cancer	3.28e-06	1.14e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—lung cancer	3.27e-06	1.14e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—lung cancer	3.26e-06	1.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—lung cancer	3.25e-06	1.13e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—lung cancer	3.22e-06	1.12e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—lung cancer	3.2e-06	1.12e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ALB—lung cancer	3.18e-06	1.11e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—lung cancer	3.14e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—lung cancer	3.1e-06	1.08e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—lung cancer	3.06e-06	1.07e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—lung cancer	3.01e-06	1.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—lung cancer	3.01e-06	1.05e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—EP300—lung cancer	2.99e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—lung cancer	2.97e-06	1.04e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—lung cancer	2.95e-06	1.03e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—lung cancer	2.8e-06	9.78e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—lung cancer	2.78e-06	9.69e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—lung cancer	2.74e-06	9.56e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—lung cancer	2.61e-06	9.12e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—lung cancer	2.42e-06	8.45e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—EP300—lung cancer	2.31e-06	8.06e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—lung cancer	2.22e-06	7.73e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—lung cancer	2.14e-06	7.45e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—lung cancer	1.81e-06	6.31e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—lung cancer	1.71e-06	5.96e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—lung cancer	1.4e-06	4.87e-06	CbGpPWpGaD
